BridgeBio Pharma BBIO License and services revenue — Contract with customer, liability
Discontinued — last reported Q1 '24
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's license and services revenue — contract with customer, liability.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's license and services revenue — contract with customer, liability?
- BridgeBio Pharma (BBIO) reported license and services revenue — contract with customer, liability of $135M in Q1 2024.
- What does license and services revenue — contract with customer, liability mean?
- Payments received from customers for work that has not yet been completed.
- How do you interpret license and services revenue — contract with customer, liability?
- An increase suggests strong upfront payments from new partnerships, while a decrease indicates the company is successfully fulfilling its contractual obligations.
- How does license and services revenue — contract with customer, liability compare across companies?
- Standard accounting metric for deferred revenue; comparable to 'Deferred Revenue' or 'Contract Liabilities' on the balance sheet of any firm using ASC 606.